TEDct Newletter Summer 2021 | oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Patient Education

TEDct Newletter Summer 2021

key information

source: TEDct

year: 2021

summary/abstract:

Welcome to the latest TEDct newsletter. In this issue, the Bristol Eye Hospital ophthalmology team have addressed a few questions commonly asked by TED patients.

 

These Included:

How to get a second opinion

Does the new drug Teprotumumab offer hope to TED sufferers?

Can diet have an impact on TED? 

 

Thyroid eye disease is a relatively rare condition that challenges sufferers physically, functionally and psychologically. It is important that affected people receive appropriate care from healthcare professionals with an understanding of the condition. One of our goals at TEDct is to educate more doctors, nurses, optometrists and other healthcare staff to provide excellent care for the condition. However, we often hear from TEDct members that it can be challenging to gain access to knowledgeable professionals. This article will cover how to know if a second opinion is appropriate for you, and how to go about seeking one if needed.

 

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

Brought to you by

Supported through an independent
educational grant by

© 2022 rareLife solutions Inc.